AHA 2023 To the suprise of the investigators of the AZALEA-TIMI 71 trial, the Data Safety Monitoring Committe recommended early termination of the phase 2 trial with the FXI inhibitor abelacimab in patients with AF. What are the findings of an interim analysis?

AHA 2023 In the ARTESIA trial, patients with subclinical AF were randomized to apixaban or aspirin and followed for stroke or systemic embolism and major bleeding. Jeff Healey discusses the results.

AHA 2023 Apixaban reduced stroke or systemic embolism in patients with subclinical atrial fibrillation compared with aspirin in the ARTESIA trial. Apixaban increased the risk of major bleeding but there was no increase intracranial bleeding or fatal bleeding.

AHA 2023 What are the findings of a phase 2 trial in which two doses of the FXI/XIa inhibitor abelacimab were compared with rivaroxaban with regard to the safety outcome of bleeding in patients with AF?

ESC Congress 2023 The results of the INTERASPIRE survey call for action to improve secondary prevention of CHD globally. Joris Holtrop interviews John McEvoy about the study results.

ESC Congress 2023 Marco Valgimigli gives his view on the results of the STOPDAPT-3 study and discusses the added value of the insights from this study in the optimization of antithrombotic therapy post-PCI.

The AZALEA-TIMI 71 trial, in which the efficacy of the factor XI/XIa inhibitor abelacimab was compared with rivaroxaban in patients with AF at moderate-to-high risk of stroke, has been stopped early due to an overwhelming reduction in bleeding.

ESC Congress 2023 An analysis of the RIVER trial showed that among patients with atrial fibrillation or flutter and a bioprosthetic mitral valve, patients with rheumatic heart disease did not have an increased risk of thrombotic and bleeding events.

ESC Congress 2023 In cancer patients with isolated distal deep vein thrombosis (DVT), 12 months of edoxaban treatment was superior to 3 months in lowering thrombotic risk, without increasing bleeding risk.

ESC Congress 2023 In the FRAIL-AF trial, frail older adults with AF were randomized to switch from a VKA to a DOAC or to continue using a VKA. Linda Joosten talks about the unexpected results of this trial.

ESC Congress 2023 The FRAIL-AF trial showed that frail older patients with AF who switched from VKA to a DOAC had a 69% higher risk of bleeding, compared with patients who continued using VKA. There was no difference between DOACs and VKA in stroke reduction in this patient population.

ESC Congress 2023 Atrial high-rate episodes resemble atrial fibrillation and clinicians may prescribe oral anticoagulation for these patients, but evidence of effectiveness is lacking. Therefore, the NOAF-AFNET 6 trial was performed.